Skip to main content

Table 5 Comparison of the demographic and clinical characteristics of GENOA participants to the general population of CATC patients

From: Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria

Demographic and clinical characteristics

CATC population level data, N = 1354

GENOA sample, n = 394

Statistical significance observed testing differences between groups

Mean age (SD)

38.4 (10.7)

38.5 (10.9)

0.87

Sex (percentage male)

66.9

53.3

p <0.05

Mean duration on MMT in years (SD)

2.1 (1.2)

4.3 (4)

p <0.05

Mean methadone dose in mg per day (SD)

81.9 (53.5)

78.1 (41.2)

0.19

Hepatitis C positive %

29.9

22.3

p <0.05

HIV positive %

0.3

0.8

0.19

Marital status (% single, divorced)

64.8

68.2

0.19

  1. Two-sample t test used to assess for differences between groups (CATC and GENOA) for continuous values
  2. Chi-square test used to assess for differences between groups for categorical variables
  3. GENOA Genetics of Opioid Addiction, CATC Canadian Addiction Treatment Centres, SD standard deviation, MMT methadone maintenance treatment, HIV human immunodeficiency virus
Back to article page

Trials

ISSN: 1745-6215